Paricalcitol
Paricalcitol is a synthetic variety of vitamin D. Paricalcitol is used to prevent and treat
secondary hyperparathyroidism associated with chronic renal failure, especially those on
kidney dialysis. It is used to treat and prevent high levels of a certain natural substance called
the parathyroid hormone in patients with long-term kidney disease. Parathyroid hormone
controls the concentrations of calcium and phosphorus in the blood. In these patients, these
low levels of calcium and a certain kind of vitamin D lead to high levels of parathyroid
hormone present in the body. Higher than desirable levels of this hormone causes serious
bone disorders and certain other serious health issues. Paricalcitol is used to reduce these
higher than healthier levels parathyroid hormone.
Abbott Laboratories market Paricalcitol, under the trade name Zemplar.
Teva Pharmaceuticals USA currently owns the patent to Paricalcitol. However, It was
patented in 1989 and approved for medical use in 1999 by the FDA, after the expiry of the
initial patents other manufacturers have been assigned a different type of approvals for
different preparations, however, the current patent is owned by Teva Pharma, USA.
Dosage and forms
Paricalcitol is sold as an injectable solution in 2mg and 5mg vials and capsules. The initial
dosage prescribed in the treatment of Secondary Hyperparathyroidism is 0.04mg-0.1mg, 3
times a week. In patients who have already progressed to stages, 3 and 4 of chronic kidney
disease, a dosage of 1 to 2mcg, up to 3 times a week is prescribed. In children age 10-16, the
recommended daily dose in between 1 and 3 mcg, whereas for children younger than that, the
doctor decides on the dosage.
The wholesale cost of Paricalcitol
In the USA, Paricalcitol intravenous solution (2 mcg/mL) costs around $94 for a supply of 25
ml, whereas the same quantity of medicine can cost from 60pounds per month onwards.
How does Paricalcitol work?
It is an analogue of 1,25-dihydroxyergocalciferol, the active form of vitamin D₂ and is an
agonist of the vitamin D receptor which lowers parathyroid hormone levels. Vitamin D needs
two sequential hydroxylations inside the liver and the kidney to bind and activate the vitamin
D receptor (VDR). It works by binding to the vitamin D receptor and has been shown to
reduce parathyroid hormone levels. Paricalcitol increases the expression of a tumor-
suppressor gene, resulting in tumor cell suicide and tumor cell differentiation into normal its
form and structure observable. Paricalcitol reduces parathyroid hormone levels and may help
better absorb calcium and phosphorus.
Finding Paricalcitol manufacturers and suppliers
Paricalcitol is lifesaving drug, it is important that you are able to find the right and trusted
supplier. However, given the wide range of manufacturers and suppliers this can be
challenging and confusing. This can be achieved by using piplelinepharma, one of the
world’s largest online B2B marketplace for drugs and pharmaceuticals. On top of the search,
it also lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also,
it is an easy to use online platform to grow your business opportunities.
The robust search engine makes it convenient to search for manufacturers and suppliers of
Paricalcitol. The search can be further refined with industry-specific filters such as dossier
type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get
in contact with the preferred manufacturer and supplier readily.